• MONA M. EL-MAHDY Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
  • MAI M. RASHEEDY Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
  • ELSAYED A. IBRAHIM Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
  • DINA FATHALLAH Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt


Objective: This study was undertaken to determine the bioavailability of ondansetron gel in experimental animals and humans applying UPLC as an analytical tool and evaluation of the antiemetic effect of ondansetron gel in cisplatin-induced emesis in rats.

Methods: Ondansetron gel (F13: sodium alginate 7% w/w) was used, marketed I. V. ondansetron (Zofran) ® was chosen as reference. The bioavailability study in rabbits was selected as a parallel design using nine healthy rabbits divided into three groups whereas, bioavailability study in humans was an open-label, wherein 6 healthy subjects administered ondansetron gel. The potential effect of ondansetron gel was evaluated for the prevention of different phases of emesis motivated by exposure to antineoplastic drugs (cisplatin) by determination of body weight loss, water and food intake applying kaolin-pica model in rats using seventy-two rats divided into six groups.

Results: Ondansetron gel (0.5%) showed detectable plasma concentration 22.833±2.17 ng/m1 after ¼ h and 419.55±2.17 ng/ml after 1-h post-treatment in rabbits and human respectively and concentration was maintained above-reported minimum effective concentration for more than 2.5 h for rabbits and 7 h for humans compared to 1.75 h after I. V. administration.

The ondansetron gel significantly reduces all phases of cisplatin-induced emesis and a decrease in body weight, water, and food consumption was significantly attenuated.

Conclusion: Based on the high efficacy of gel on emesis induced by cisplatin, and its high bioavailability, transdermal ondansetron gel could be a promising convenient system to prevent nausea and vomiting following administration of antineoplastic drugs.

Keywords: Ondansetron, Transdermal gel, Bioavailability, UPLC, Cisplatin-induced emesis in rats


Download data is not yet available.


1. Patel DR, Joshi A, Patel HH, Stagni G. Development and in vivo evaluation of ondansetron gels for transdermal delivery. Drug Dev Ind Pharm 2015;41:1030-6.
2. Maraie NK, Almajidi YQ, Alshader A. Absolute and relative bioavailability study for the newly developed nasal nanoemulsion in situ gel of ondansetron Hcl in comparison to conventionally prepared in situ gel and intravenous dosage forms. Int J Appl Pharm 2018;10:105-9.
3. Atashkhoei S, Bilehjani E, Fakhari S, Hanieh F. Postoperative nausea and vomiting prophylaxis with ondansetron in diagnostic gynecologic laparoscopy: preemptive versus preventive method. AJARS 2017;5:1-9.
4. Tomasik E, Ziolkowska E, Kolodziej M, Szajewska H. Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. Aliment Pharmacol Ther 2016;44:438-46.
5. Menaka M, Pandey VP, Anton SA. Colloidal dispersions as a potential nasal drug delivery system for ondansetron hydrochloride-in vitro and in vivo properties. Asian J Pharm Clin Res 2014;7:72-5.
6. O'Neil MJ. The merck index: an encyclopedia of chemicals, drugs, and biologicals: RSC Publishing; 2013. p. 1270.
7. Kumar A, Adhana S, Dwivedi P. A comparison of intravenous ondansetron and paloseron in preventing postoperative nausea and vomiting after laproscopic cholecystectomy-A randomized double-blind study. Asian J Pharm Clin Res 2018;11:128-31.
8. Khan S, Kataria P, Nakhat P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS PharmSciTech 2007;8:E127-33.
9. Rasheedy MM, El-Mahdy MM, Fathallah D, Ibrahim EA. Formulation and evaluation of ondansetron transdermal gels. Bull Pharm Sci Assiut 2017;40:57-70.
10. Panchagnula R, Thomas NS. Biopharmaceutics and pharmacokinetics in drug research. Int J Pharm 2000;201:131-50.
11. Emami J. In vitro-in vivo correlation: from theory to applications. J Pharm Pharm Sci 2006;9:169-89.
12. Leopold CS. How accurate is the determination of the relative bioavailability of transdermal drug formulations from pharmacodynamic response data? Pharm Acta Helv 1998;73:63-7.
13. Andrews PL, Rapeport WG, Sanger GJ. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 1988;9:334-41.
14. Kilpatrick GJ, Bunce KT, Tyers MB. 5?HT3 receptors. Med Res Rev 1990;10:441-75.
15. Tyers MB. 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists. Therapie 1991;46:431-5.
16. Sharma V, Arora S. Emesis during chemotherapy: A review on granisetron, its efficacy and delivery systems. Int J Curr Pharm Res 2015;7:11-8.
17. Minami M, Ogawa T, Endo T, Hamaue N, Hirafuji M, Yoshioka M, et al. Cyclophosphamide increases 5-hydroxytryptamine release from the isolated ileum of the rat. Res Commun Mol Pathol Pharmacol 1997;97:13-24.
18. Andrews PL, Horn CC. Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 2006;125:100-15.
19. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark Snow R, Koeller JM, et al. American society of clinical oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006;24:2932-47.
20. Kris MG, Gralla RJ, Clark RA, Tyson LB, O'Connell JP, Wertheim MS, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 1985;3:1379-84.
21. Andrews P, Bhandari P. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 1993;29:S11-6.
22. Rudd JA, Naylor RJ. An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 1996;118:209-14.
23. Aapro MS. 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991;42:551–68.
24. Morrow GR, Hickok JT, Rosenthal SN. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban). Cancer 1995;76:343-57.
25. Rudd JA, Jordan CC, Naylor RJ. Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. Eur J Pharmacol 1994;262:R1-2.
26. King GL. Animal models in the study of vomiting. Can J Physiol Pharmacol 1990;68:260-8.
27. Takeda N, Hasegawa S, Morita M, Matsunaga T. Pica in rats is analogous to emesis: an animal model in emesis research. Pharmacol Biochem Behav 1993;45:817-21.
28. Saeki M, Sakai M, Saito R, Kubota H, Ariumi H, Takano Y, et al. Effects of HSP-117, a novel tachykinin NK1-receptor antagonist, on cisplatin-induced pica as a new evaluation of delayed emesis in rats. Japan J Pharmacol 2001;86:359-62.
29. Rudd JA, Yamamoto K, Yamatodani A, Takeda N. Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption (“pica”) in rats. Eur J Pharmacol 2002;454:47-52.
30. Yamamoto K, Matsunaga S, Matsui M, Takeda N, Yamatodani. A pica in mice as new model for the study of emesis. Methods and findings. Exp Clin Pharmacol 2002;24:135-8.
31. Qureshi MJ, Ali J, Baboota S, Ahuja A, Mallikarjun C. Pharmacokinetic study of a capsule-based chronomodulated drug delivery system of salbutamol sulphate in rabbits. Trop J Pharm Res 2014;13:17-22.
32. Karim S, Hay YK, Baie SH, Bukhari NI, Murtaza G. Study of comparative bioavailability of omeprazole pellets. Acta Pol Pharm 2014;71:463-8.
33. Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 2012;18:2913-21.
34. Howell J, Smeets J, Drenth HJ, Gill D. Pharmacokinetics of a granisetron transdermal system for the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 2009;15:223-31.
35. Koland M, Charyulu RN, Vijayanarayana K, Prabhu P. In vitro and in vivo evaluation of chitosan buccal films of ondansetron hydrochloride. Int J Pharm Investig 2011;1:164-71.
36. Sheshala R, Khan N, Chitneni M, Darwis Y. Formulation and in vivo evaluation of ondansetron orally disintegrating tablets using different superdisintegrants. Arch Pharm Res 2011;34:1945-56.
37. Wu Z, Zhang C, Yang C, Zhang X, Wu E. Simultaneous quantitative determination of norgestrel and progesterone in human serum by high-performance liquid chromatography-tandem mass spectrometry with atmospheric pressure chemical ionization. Analyst 2000;125:2201-5.
38. Singh RK, Ramakrishna S, Gupta P. RP-HPLC method development and validation for simultaneous estimation of ranitidine hydrochloride and domperidone in combined tablet dosage form. Int J Pharm Sci Res 2010;1:77.
39. Chen FC, Wang LH, Guo J, Shi XY, Fang BX. Simultaneous determination of dexamethasone, ondansetron, granisetron, tropisetron, and azasetron in infusion samples by HPLC with DAD detection. J Anal Methods Chem 2017;2017:1-7.
40. Gibaldi M. Biopharmaceutics and clinical pharmaceutics. 4th edition ed. Philadelphia, USA; 1991. p. 147, 205, 337.
41. Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK. Poison induced pica in rats. Physiol Behav 1976;17:691-7.
42. Aung HH, Mehendale SR, Xie JT, Moss J, Yuan CS. Methylnaltrexone prevents morphine-induced kaolin intake in the rat. Life Sci 2004;74:2685-91.
43. Liu YL, Malik N, Sanger GJ, Friedman MI, Andrews PL. Pica-a model of nausea? Species differences in response to cisplatin. Physiol Behav 2005;85:271-7.
44. Du Sert NP, Rudd J, Apfel C, Andrews PJCc, pharmacology. Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT 3 receptor antagonists. Cancer Chemother Pharmacol 2011;67:667-86.
45. Shi J. Evaluating the various phases of cisplatin?induced emesis in rats. Oncol Lett 2014;8:2017-22.
46. Repetto MR, Repetto M. Concentrations in human fluids: 101 drugs affecting the digestive system and metabolism. J Toxicol Clin Toxicol 1999;37:1-9.
47. Ahmed TA. Basic pharmacokinetic concepts and some clinical applications: BoD–Books on Demand; 2015.
48. British Medical Association, Joint Formulary Committee (Great Britain), Pharmaceutical Society of Great Britain. British national formulary. Pharmaceutical Pr; 2003.
49. Malik NM, Liu YL, Cole N, Sanger GJ, Andrews PL. Differential effects of dexamethasone, ondansetron and a tachykinin NK1 receptor antagonist (GR205171) on cisplatin-induced changes in behaviour, food intake, pica and gastric function in rats. Eur J Pharmacol 2007;555:164-73.
50. Malik NM, Moore GB, Smith G, Liu YL, Sanger GJ, Andrews PL. Behavioural and hypothalamic molecular effects of the anti-cancer agent cisplatin in the rat: a model of chemotherapy-related malaise? Pharmacol Biochem Behav 2006;83:9-20.
51. De Jonghe BC, Lawler MP, Horn CC, Tordoff MG. Pica as an adaptive response: Kaolin consumption helps rats recover from chemotherapy-induced illness. Physiol Behav 2009;97:87-90.
52. Cabezos P, Vera G, Martin Fontelles M, Fernandez Pujol R, Abalo R, Motility. Cisplatin?induced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. Neurogastroenterol Motil 2010;22:797-e225.
53. Gordon JA, Peterson LN, Anderson RJ. Water metabolism after cisplatin in the rat. Am J Physiol 1982;243:F36-43.
54. Bradner WT, Schurig JE. Toxicology screening in small animals. Cancer Treat Rev 1981;8:93-102.
55. Olver IN, Roos IA, Thomas K, Hillcoat BL. Development of a murine gastric distension model for testing the emetic potential of new drugs and efficacy of antiemetics. Chem Biol Interact 1989;69:353-7.
56. Broomhead J, Fairlie D, Whitehouse MW. Cis-Platinum (II) amine complexes: some structure-activity relationships for immunosuppressive, nephrotoxic and gastrointestinal (side) effects in rats. Chem Biol Interact 1980;31:113-32.
57. Bearcroft CP, Domizio P, Mourad FH, Andre EA, Farthing MJ. Cisplatin impairs fluid and electrolyte absorption in rat small intestine: a role for 5-hydroxytryptamine. Gut 1999;44:174-9.
58. Riezzo G, Clemente C, Linsalata M, D'Attoma B, Orlando A, Campanella G, et al. Gut peptide profile and chemotherapy-associated dyspepsia syndrome in patients with breast cancer undergoing FEC60 chemotherapy. Anticancer Res 2013;33:4951-7.
59. Phillips TD, Sarr AB, Grant PG. Selective chemisorption and detoxification of aflatoxins by phyllosilicate clay. Nat Toxins 1995;3:204-13.
60. Phillips TD. Dietary clay in the chemoprevention of aflatoxin-induced disease. Toxicol Sci 1999;52 Suppl 1:118-26.
61. Beck I, Jenkins N, Thurber L, Ambrus JL. Methods for the study of antidiarrheal agents. Study of commonly used protective and adsorbent agents. J Med 1977;8:135-58.
139 Views | 219 Downloads
How to Cite
Original Article(s)